GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shield Therapeutics STX.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

3.15p

-1.56%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shield Therapeutics

Its shares trade on LSE under the ticker STX.L. It has been listed since 26 February 2016. In the fiscal year to 31 December 2024, it reported revenue of $32.2m and a net loss of $27.2m. At that date it held total assets of $57.5m and shareholders' equity of −$1.3m.

Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear. The company went IPO on 2016-02-26. The firm's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. The company also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
26 Feb 2016
Employees
18

Leadership

Pay as last reported

  • Mr. Hans HaslerNon-Executive Independent Chairman of the Board£128,000
  • Mr. Anders LundstromChief Executive Officer, Executive Director, since 2021£154,000
  • Mr. Peter Llewellyn-DaviesNon-Executive Independent Vice Chairman of the Board, since 2024£61,000
  • Mr. Santosh ShanbhagChief Financial Officer
  • Ms. Lucy Huntington-BaileyChief Compliance Officer, General Counsel, Company Secretary
  • Mr. David ChildsVice President - Manufacturing and Strategic Alliances, since 2023
  • Dr. Jackie MitchellVice President - Quality, Clinical and Regulatory Affairs, since 2024
  • Mr. Andy HurleyChief Commercial Officer
  • Dr. Christian SchweigerNon-Executive Director£51,000
  • Dr. Rudolf WidmannNon-Executive Director£25,000
  • Ms. Fabiana Lacerca-AllenNon-Executive Independent Director£51,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.